A Review on Signal in Pharmacovigilance
A safety signal is data or information that may suggest a new causal association, or contribute new information about a known association, between a medicine and an adverse event that justifies further investigation. Signals are generated from several sources such as spontaneous reports, clinical studies and the scientific literature. Signal is a potential medicine safety issues, which are derived from individual case safety reports in vigiBase. Signal detection is a cornerstone of drug development process ensuring drug safety. The early detection of Signals helps to improve patient safety and reduce economic burden due to escalating cost of medications and unwanted adverse effects associated with it. The present study is an initiative to make significant contribution towards health-care system by generating evidence based data to benefit health care professionals, consumers, pharmaceutical companies and regulatory authorities.Signal detection and signal strengthening is the most important aspect in Pharmacovigilance which plays an important role in ensuring that patients receive safe drugs. For detection of adverse drug reactions, clinical trials usually provide limited information as they are conducted under strictly controlled conditions. Some of the adverse drug reaction can be detected only after long term use in larger population and in specific patient groups due to specific concomitant medications or disease.
2. World Health Organization. Pharmacovigilance: ensuring the safe use of medicines. Geneva: World Health Organization; 2004.
3. Zhengwu Lu. Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives: Drug, Healthcare and patient Safety. 2009; 135-45.
4. World Health Organization: The importance of Pharmacovigilance Safety Monitoring of Medicinal products: 2002.
5. Prakash S. Pharmacovigilance in India. Indian Journal of Pharmacology. 2007; 39(3).
6. Zhengwu Lu. Information technology in pharmacovigilance: Benefits, challenges, and future directions from industry perspectives: Drug, Healthcare and patient Safety. 2009; 135-45.
7. ADRs reporting systems and signal detection. Viewpoint, Part 2, the Uppsala Monitoring Centre. 2005
8. Edwards IR, Aronson JK (2000) adverse drug reactions: Definitions, diagnosis, and management. Lancet 356:1255
9. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Annals of internal medicine. 2004; 140(10):795-801.
10. Patel KJ, Kedia MS, Bajpai D, Mehta SS, Kshirsagar NA, Gogtay NJ. Evaluation of the prevalence and economic burden of adverse drug reactions presenting to the medical emergency department of a tertiary referral centre: a prospective study. BMC Clin Pharm 2007; 7:1-5.
11. Chakraborty BS. Pharmacovigilance: A data mining approach to signal detection. Indian journal of pharmacology. 2015; 47(3):241.
12. World Health Organization (WHO) guidelines on safety monitoring of herbal medicines in pharmacovigilance systems, World Health Organization, Geneva: WHO 2004.
13. Chakraborty BS. Pharmacovigilance: A data mining approach to signal detection. Indian journal of pharmacology. 2015; 47(3):241.
14. ADRs reporting systems and signal detection. Viewpoint, Part 2, the Uppsala Monitoring Centre. 2005.
15. Mubasheera Mg, Pharmacovigilance (PV) continue signal detection, Department of Pharmacy, Nov-20, 2007.
16. ADRs reporting systems and signal detection. Viewpoint, Part 2, the Uppsala Monitoring Centre. 2005
17. Kumar anoop, Khan Henna, Signal detection and their assessment in Pharmacovigilance, Departmental of pharmaceutical science. Open pharmaceutical science journal, 2015; 2:66-73.
18. S.K Gupta, Signal detection in Pharmacovigilance, A textbook of Pharmacovigilance, 2011:- 60-74.
19. Ronald H.B. Meyboom,1,2,3 Marie Lindquist,1 Antoine C.G. Egberts 2,4 and I. Ralph Edwards, Signal Selection and Follow-Up in Pharmacovigilance, Drug Safety 2002; 459-465.
20. CIOMS working Group. Practical aspects of signal detection in pharmacovigilance. Geneva; 2010(8).
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).